Suzuki and Ishihara, clear explanation differences between fully FDA approved Patisiran interfering siRNA for amyloid an...
Jul 8th 2022 5:57am EDT
Suzuki and Ishihara, clear explanation differences between fully FDA approved Patisiran interfering siRNA for amyloid and EUA BLA investigational genetic products forced for 18 months in the indiscriminate mandated program. LNP carrier organ seeding, Spike adverse safety profile. @PeterMcCulloughMD www.PeterMcCulloughMD.com Powered by WPeMatico
Promote it on DissentWatch!
- To advertise this post for $0.02 per visit send bitcoins to the address below
- The post will be promoted daily via social media & our "Featured News" display in multiple places
- You can add more anytime
- Ranking order in the Featured News box is based on the balance remaining
Received: 0 mBTC (0.00 USD)
Spent: 0 mBTC (0.00 USD)
Balance: 0 mBTC (0.00 USD)
The amounts above may be lagging behind. If you just sent a payment click below to get more up to date results and push the post to the "Featured News" box faster.